JENA, Germany, Oct. 17 /CNW/ - Occlutech GmbH, the leading European
developer and manufacturer of cardiac occlusion devices such as ASD, PFO and
LAA occluders today announced that it has received CE mark approval for its
range of ASD and PFO occluder under the Occlutech Figulla N brand.
The Occlutech ASD and PFO occluders are uniquely designed and
individually braided, improving performance over existing technology. The fact
that the occluders are not clamped gives them distinct advantages such as
increased flexibility and a reduction of the amount of material implanted.
Occlutech's technology is protected by several patents and patents
Starting in Germany, the products will be rolled out in Europe and in
International markets over the next few months.
Occlusion devices are used to treat structural heart disease, including
structural heart defects and abnormalities, such as Atrial Septal Defects
(ASD), or Patent Foramen Ovale (PFO), in a minimally invasive, non-surgical
way. The market for these devices, and the PFO occluders in particular, are
expected to expand significantly over the next few years.
For further information:
For further information: Robert Moszner, e-mail:
email@example.com, phone: +49-3641-67-51-20; Susanne Goransson,
e-mail: firstname.lastname@example.org, phone: +46-704-336521